AXIM Stock Overview
Engages in the development and sale of diagnostic healthcare solutions in the areas of SARS-CoV-2, eye health, and other diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
AXIM Biotechnologies, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0039 |
| 52 Week High | US$0.022 |
| 52 Week Low | US$0.002 |
| Beta | 1.11 |
| 11 Month Change | -2.62% |
| 3 Month Change | -53.57% |
| 1 Year Change | -77.84% |
| 33 Year Change | -99.02% |
| 5 Year Change | -99.15% |
| Change since IPO | -93.50% |
Recent News & Updates
Recent updates
Shareholder Returns
| AXIM | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -2.5% | -7.5% | -1.2% |
| 1Y | -77.8% | 14.1% | 30.4% |
Return vs Industry: AXIM underperformed the US Biotechs industry which returned 14.1% over the past year.
Return vs Market: AXIM underperformed the US Market which returned 30.4% over the past year.
Price Volatility
| AXIM volatility | |
|---|---|
| AXIM Average Weekly Movement | 33.4% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: AXIM's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: AXIM's weekly volatility (33%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 7 | n/a | www.aximbiotech.com |
AXIM Biotechnologies, Inc. engages in the development and sale of diagnostic healthcare solutions in the areas of SARS-CoV-2, eye health, and other diseases. The company is developing tests for dye eye diseases; SARS-CoV-2 neutralizing antibody tests; and fentanyl neutralizing antibody tests. It also developing a line of novel diagnostics for early cancer detection, response to treatment, and recurrence monitoring.
AXIM Biotechnologies, Inc. Fundamentals Summary
| AXIM fundamental statistics | |
|---|---|
| Market cap | US$1.22m |
| Earnings (TTM) | -US$4.14m |
| Revenue (TTM) | US$92.90k |
13.1x
P/S Ratio-0.3x
P/E RatioIs AXIM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AXIM income statement (TTM) | |
|---|---|
| Revenue | US$92.90k |
| Cost of Revenue | US$1.74k |
| Gross Profit | US$91.15k |
| Other Expenses | US$4.23m |
| Earnings | -US$4.14m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.013 |
| Gross Margin | 98.12% |
| Net Profit Margin | -4,452.06% |
| Debt/Equity Ratio | -69.2% |
How did AXIM perform over the long term?
See historical performance and comparison